Retinal Neovascularization
Conditions
Keywords
Retinal neovascularization, Anti-VEGF, Retinal Nerve Fiber Layer (RNFL)
Brief summary
The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is currently the standard treatment for retinal neovascularization. The VEGF stimulates endothelial cells' proliferation and migration. It also increases microvascular permeability. If the VEGFs have proven their efficiency in the decrease of choroidal neovascular proliferation, their impact of the head of the optic nerve's microvasculature is yet unknown. Knowing that this microvasculature provides the retinal nerve fibers with oxygen, located in the area of the head of the optic nerve, a vasoconstriction induced by the anti-VEGF may have an incidence on the loss of retinal nerve fibers.
Interventions
DEVICEGonioscopy
Study of the trabecular structure by gonioscopy
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years old * Patients treated with anti-VEGF according to the French summary of product characteristics (SPC) * Patients who have been informed of the trial and who are not opposed to participate in the study
Exclusion criteria
* Patients presenting a retinal condition, including the optic nerve * Patients treated with anti-VEGF in both eyes * Pregnant women * Lack of affiliation to social security or universal health coverage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in RNFL's thickness in the nasal quadrant of the optic nerve after intra-vitreous Injection of Anti-VEGF | Change from baseline RNFL's thickness at Month 12 | RNFL's thickness (in microns) measured with the Heildelberg glaucoma module of the spectral domain Optical Cohérence Tomographie (OCT Spectralis, Heidelberg engeening). |
Countries
France
Outcome results
None listed